Establish regional biologic manufacturing hubs (Africa, South Asia, Southeast Asia) that hold pre-negotiated compulsory license agreements with originator companies, activated within 90 days of WHO Essential Medicine listing. Each hub handles 3-5 biologic products simultaneously, reducing per-dose costs by 60-75%. Hubs are co-owned by regional governments, funded through CEPI/Gavi advance purchase commitments.